Compare Amylx Pharmaceuticals Inc (AMLX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Ulta Beauty Inc trades at $469.2 (market cap $20.17B). The key difference: Ulta Beauty Inc is far larger — about 10.2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | ULTA | |
|---|---|---|
Market Cap | $1.98B | $20.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $706.82 |
52-Week Low | $7.64 | $450.75 |
Enterprise Value | $1.70B | $22.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
ULTA Beauty trades at $469.20, up 1.95% on the day, with a bearish technical signal but strong fundamentals including a 9.36% net income margin and 47.45% ROE. Recent Q1 2026 earnings beat expectations at $7.74 EPS versus $6.89. The stock is near its pivot point of $457, with resistance at $470. Positive news highlights international expansion and a robust loyalty program driving 95% of sales.
The outlook is mixed: analyst consensus is bullish with a $623.73 price target, but technicals and recent net cash flow negativity pose risks. Investment opportunity lies in market share gains and AI-driven personalization, while headwinds include competitive pressures and margin compression from 11.42% in 2022 to 9.35% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
